LU92218I9 - - Google Patents

Info

Publication number
LU92218I9
LU92218I9 LU92218C LU92218C LU92218I9 LU 92218 I9 LU92218 I9 LU 92218I9 LU 92218 C LU92218 C LU 92218C LU 92218 C LU92218 C LU 92218C LU 92218 I9 LU92218 I9 LU 92218I9
Authority
LU
Luxembourg
Prior art keywords
bladder
rat
urination
rhythmic
measurement test
Prior art date
Application number
LU92218C
Other languages
English (en)
French (fr)
Other versions
LU92218I2 (fr
Inventor
Toshiyuki Takasu
Shuichi Sato
Masashi Ukai
Tatsuya Maruyama
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92218(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of LU92218I2 publication Critical patent/LU92218I2/fr
Publication of LU92218I9 publication Critical patent/LU92218I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU92218C 2002-11-07 2013-06-17 Mirabegron ou un de ses sels LU92218I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07

Publications (2)

Publication Number Publication Date
LU92218I2 LU92218I2 (fr) 2014-01-07
LU92218I9 true LU92218I9 (OSRAM) 2019-01-17

Family

ID=32310425

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92218C LU92218I2 (fr) 2002-11-07 2013-06-17 Mirabegron ou un de ses sels

Country Status (28)

Country Link
US (5) US20060115540A1 (OSRAM)
EP (1) EP1559427B1 (OSRAM)
JP (1) JP3815496B2 (OSRAM)
KR (1) KR100967070B1 (OSRAM)
CN (1) CN100406011C (OSRAM)
AT (1) ATE500827T1 (OSRAM)
AU (1) AU2003284700B2 (OSRAM)
BE (1) BE2013C040I2 (OSRAM)
BR (1) BR0316080A (OSRAM)
CA (1) CA2503570C (OSRAM)
CY (2) CY1111399T1 (OSRAM)
DE (1) DE60336334D1 (OSRAM)
DK (1) DK1559427T3 (OSRAM)
ES (1) ES2360353T3 (OSRAM)
FR (1) FR13C0032I2 (OSRAM)
HU (1) HUS1300027I1 (OSRAM)
IL (1) IL168121A (OSRAM)
LU (1) LU92218I2 (OSRAM)
MX (1) MXPA05004925A (OSRAM)
NL (1) NL300599I2 (OSRAM)
NO (2) NO334948B1 (OSRAM)
NZ (1) NZ539577A (OSRAM)
PL (1) PL211687B1 (OSRAM)
PT (1) PT1559427E (OSRAM)
RU (1) RU2321401C2 (OSRAM)
SI (1) SI1559427T1 (OSRAM)
WO (1) WO2004041276A1 (OSRAM)
ZA (1) ZA200503510B (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
PT2216021E (pt) 2007-11-02 2012-11-06 Astellas Pharma Inc Composição farmacêutica para tratar uma bexiga hiperactiva
CA2709727A1 (en) 2007-12-21 2009-07-02 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
JP5553767B2 (ja) * 2008-11-07 2014-07-16 大日本住友製薬株式会社 新規で有用な下部尿路症状治療剤
US8586760B2 (en) * 2009-06-15 2013-11-19 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
JP5849946B2 (ja) * 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
EP2709993A4 (en) * 2011-05-18 2015-02-25 Reddys Lab Ltd Dr AMORPHIC MIRABEGRON AND METHOD FOR CRYSTALLINE FORMS OF MIRABEGRON
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
US20150031734A1 (en) 2012-03-30 2015-01-29 Astellas Pharma Inc. Pharmaceutical composition containing mirabegron
KR20150045500A (ko) 2012-08-31 2015-04-28 아스텔라스세이야쿠 가부시키가이샤 경구 투여용 의약 조성물
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103193658A (zh) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
ES2910361T3 (es) * 2013-07-23 2022-05-12 Serenity Pharmaceuticals Llc Composiciones que comprenden desmopresina en combinación con un agonista del receptor adrenérgico beta-3
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
CN106999538A (zh) 2014-11-20 2017-08-01 阿勒根公司 包含去氨加压素与α‑肾上腺素能受体拮抗剂组合的方法和组合物
CN104496841B (zh) * 2014-11-26 2017-01-25 南京工业大学 一种米拉贝隆中间体的合成方法
CN104744292A (zh) * 2015-03-11 2015-07-01 南京工业大学 (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) * 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 一种米拉贝隆中间体的后处理方法
PT3360866T (pt) 2017-02-14 2019-02-19 Tiefenbacher Alfred E Gmbh & Co Kg Pró-fármacos de mirabegrom
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
EP3636256B1 (en) 2017-05-31 2024-07-03 SBI Pharmaceuticals Co., Ltd. Prophylactic or therapeutic agent for hyperactive bladder
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
WO2019013583A2 (ko) 2017-07-14 2019-01-17 주식회사 대웅제약 약제학적 제제 및 그 제조방법
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
WO2020115705A1 (en) 2018-12-05 2020-06-11 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
EP4410279A1 (en) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. A film tablet comprising mirabegron
KR20240171516A (ko) 2023-05-30 2024-12-09 주식회사 디앤아이바이오 미라베그론 서방정
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (ja) 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
HUT69285A (en) 1993-04-26 1995-09-28 Fujisawa Pharmaceutical Co Ethanolamine derivatives, pharmaceutical compns. contg. them and process to prepare the sald compds.
JPH07228543A (ja) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
DE69628051T2 (de) 1995-10-26 2004-02-26 Mitsubishi Pharma Corp. Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
WO1998000016A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
KR20000068208A (ko) 1996-08-19 2000-11-25 간자와 무츠와 빈뇨 및 요실금의 예방·치료제
AU749201B2 (en) * 1997-08-28 2002-06-20 Afferon Corporation Urinary incontinence therapy
AR017340A1 (es) 1997-10-17 2001-09-05 Astellas Pharma Inc Un derivado de amida, su uso y una composicion farmaceutica que lo comprende.
KR100545474B1 (ko) 1997-12-18 2006-01-24 깃세이 야쿠힌 고교 가부시키가이샤 페닐아미노알킬카르복실산 유도체 및 그것을 함유하는의약조성물
CA2328348C (en) 1998-04-14 2009-03-03 Kissei Pharmaceutical Co., Ltd. 2-methylpropionic acid derivatives and medicinal compositions containing the same
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
WO2000047771A2 (en) 1999-02-12 2000-08-17 Genset Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) * 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
CA2646729A1 (en) 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence

Also Published As

Publication number Publication date
PL376771A1 (pl) 2006-01-09
WO2004041276A1 (ja) 2004-05-21
CA2503570A1 (en) 2004-05-21
NL300599I2 (OSRAM) 2017-01-03
EP1559427A4 (en) 2007-05-30
JPWO2004041276A1 (ja) 2006-03-02
MXPA05004925A (es) 2005-08-18
NO334948B1 (no) 2014-08-04
AU2003284700A1 (en) 2004-06-07
RU2321401C2 (ru) 2008-04-10
NO20052691D0 (no) 2005-06-06
SI1559427T1 (sl) 2011-06-30
LU92218I2 (fr) 2014-01-07
RU2005117367A (ru) 2006-01-20
US20110230530A1 (en) 2011-09-22
US20060115540A1 (en) 2006-06-01
AU2003284700B2 (en) 2009-05-28
EP1559427B1 (en) 2011-03-09
FR13C0032I2 (fr) 2014-03-07
KR20050072809A (ko) 2005-07-12
USRE44872E1 (en) 2014-04-29
JP3815496B2 (ja) 2006-08-30
CN1711085A (zh) 2005-12-21
HUS1300027I1 (hu) 2016-08-29
NO2015001I1 (no) 2015-01-19
FR13C0032I1 (OSRAM) 2013-08-09
EP1559427A1 (en) 2005-08-03
ATE500827T1 (de) 2011-03-15
ES2360353T3 (es) 2011-06-03
PL211687B1 (pl) 2012-06-29
CY1111399T1 (el) 2015-08-05
BE2013C040I2 (OSRAM) 2023-03-07
NO2015001I2 (no) 2015-01-26
NZ539577A (en) 2007-06-29
CY2013023I2 (el) 2015-10-07
US20090093529A1 (en) 2009-04-09
DE60336334D1 (de) 2011-04-21
NO20052691L (no) 2005-07-15
US8835474B2 (en) 2014-09-16
BR0316080A (pt) 2005-09-27
PT1559427E (pt) 2011-05-27
CA2503570C (en) 2011-04-19
ZA200503510B (en) 2006-12-27
KR100967070B1 (ko) 2010-07-01
US7750029B2 (en) 2010-07-06
CN100406011C (zh) 2008-07-30
CY2013023I1 (el) 2015-10-07
DK1559427T3 (da) 2011-04-26
IL168121A (en) 2011-12-29

Similar Documents

Publication Publication Date Title
BE2013C040I2 (OSRAM)
NO20044974L (no) Imidazo [1,2-a]pyrazin-8-ylaminer, fremgangsmater for fremstilling og anvendelse derav
DE60024946D1 (de) Elektrodengürtel eines Herzfrequenzüberwachungsgerätes
EA200100826A1 (ru) 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
LU92433I2 (fr) Olodatérol, ses isomères optiques individuels, mélanges d'énantiomères individuels ou de racémates, ses sels d'addition d'acide avec des acides pharmaceutiquement acceptables, ainsi que ses solvates et/ou ses hydrates, en particulier l'olodatérol et le chlorhydrate d'olodatérol
LU90426I2 (fr) Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir
NO1994007I1 (no) Ketorolac/ 5-benzoyl-1,2-dihydro-3H-pyrrolo-[1,2-a]-pyrrol-1-karboksylsyre og dens farmasøytisk akseptable salter
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
IL164203A0 (en) Polycyclic compounds as potent alpah2-adrenoceptorantagonists
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69329057D1 (de) Messverfahren mittels Resonanz eines resonanzfähigen Körpers
NO20050888D0 (no) Ny fremgangsmate for syntesen av 1,3,4,5-tetrahydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
CN2417896Y (zh) 用于构成木人桩的围带式活动桩肢
SG153822A1 (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
DK0401093T3 (da) Hidtil ukendte pyrrolidonderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende disse
ES2120251T3 (es) 3-alcoxicarbonil-tiadiazinonas cardioactivas.
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
GB2000510A (en) Therapeutic Dipeptides
ITMI20021168A1 (it) Procedimento per la preparazione dell'acido (s)-tetraidro-a-(1-metiletil)-2-osso-1(2h)-piridinacetico
IT1141434B (it) Dispositivo per stringere il corpo di un mobile,nonche' per eseguire dei fori per accogliere mezzi di collegamento a vite
ITMI20020974A1 (it) Procedimento per la preparazione dell'acido 4-fluoro-antranilico
ITMI20000376A0 (it) Allomorfo del cloridrato dell'isomero z di derivato di alchilamminofurano procedimento per la sua produzione e composizione farmaceutica che
WO2002056870A3 (en) Method for treating sleep disorders
WO2005097113A3 (en) 5-ht2b receptor antagonists